Reuters logo
BRIEF-Benitec Biopharma anticipates meeting with regulatory agencies in early 2017 for ddRNAi treatment study
December 20, 2016 / 12:29 PM / 9 months ago

BRIEF-Benitec Biopharma anticipates meeting with regulatory agencies in early 2017 for ddRNAi treatment study

Dec 20 (Reuters) - Benitec Biopharma Ltd :

* Benitec Biopharma - “significant” progress on use of co’s technology for development of a ddRNAi based therapeutic for treatment of hepatitis b virus

* Benitec Biopharma Ltd - anticipate meeting with a number of regulatory agencies in early 2017 for the ddRNAi treatment study Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below